Pivotal phase 2 study of Obinutuzumab as Monotherapy or in combination with Zanubrutinib

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please visit beigene.com for more information.

I am a Healthcare Professional from: